EGF and GHRP6 Co-Administration Attenuates Cognitive Decline in Preclinical Models: Behavioral and Molecular Evidences.

Risco-Acevedo D, Subirós-Martínez N, Camacho-Rodríguez H, Ramírez-Sánchez J, Rodríguez-Virulich Y, Etchegoyen-Amoros AY, Hernández-Estrada W, Wong-Guerra M, Montano-Peguero Y, Estrada-Olivares T, Fuentes-Morales D, Palenzuela-Gardón D and 5 more

Show all authors

Pérez-Saad H, Núñez-Figueredo Y, Wen L, Guillén-Nieto GE, García-Del-Barco-Herrera D

Neurotoxicity research4 Jul 2026

PMID42399524DOI10.1007/s12640-026-00807-0PepBankPUB-42399524

Publisher page PubMedAsk about this study

Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone8

In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking GHRP-6.

01AnimalNot a test of GHRP-6 aloneAnimal study (in vivo)Efficacy outcome
In aged mice, EGF+GHRP6 increased step length.
In plain wordsIn mice with age-related cognitive impairment, EGF+GHRP6 increased step length.
Peptide
GHRP-6
Outcome
IncreaseStep length in aged mice
Study
mousen: not reported in source
C57BL/6 mice with age-related or STZ-induced cognitive impairment
Outcome group
Exercise and physical function · Nervous system and cognition
Source sentences
Summary
In aged animals, EGF + GHRP6 treatment increased step length (p = 0.04).
2 context sentences(design, population, supporting numbers)
Summary · context
The present study evaluated the therapeutic potential of this combination in two preclinical models of cognitive impairment: (i) age-related decline and (ii) impairment induced by intracerebroventricular administration of streptozotocin (STZ).
Summary · context
In both experiments, C57BL/6 mice were used and distributed into three experimental groups, each comprising 14-15 animals per group.
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-4239952401
02AnimalNot a test of GHRP-6 aloneAnimal study (in vivo)Efficacy outcome
In aged mice receiving EGF+GHRP6, novel arm visits exceeded familiar arm 1 visits in the forced alternation Y-maze.
In plain wordsIn aged mice receiving EGF+GHRP6, visits to the novel arm exceeded visits to familiar arm 1.
Peptide
GHRP-6
Outcome
IncreaseNovel arm visits versus familiar arm 1
Study
mousen: not reported in source
Aged C57BL/6 mice receiving EGF + GHRP6
Comparator
Familiar arm 1
Outcome group
Cognition and memory · Nervous system and cognition
Source sentences
Summary
In the forced alternation Y-maze test, aged-EGF + GHRP6 animals made more visits to the novel arm than to the familiar arm 1 (p = 0.001) or to the familiar arm 2 (p = 0.04).
2 context sentences(design, population, supporting numbers)
Summary · context
The present study evaluated the therapeutic potential of this combination in two preclinical models of cognitive impairment: (i) age-related decline and (ii) impairment induced by intracerebroventricular administration of streptozotocin (STZ).
Summary · context
In both experiments, C57BL/6 mice were used and distributed into three experimental groups, each comprising 14-15 animals per group.
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-4239952402
03AnimalNot a test of GHRP-6 aloneAnimal study (in vivo)Efficacy outcome
In aged mice receiving EGF+GHRP6, novel arm visits exceeded familiar arm 2 visits in the forced alternation Y-maze.
In plain wordsIn aged mice receiving EGF+GHRP6, visits to the novel arm exceeded visits to familiar arm 2.
Peptide
GHRP-6
Outcome
IncreaseNovel arm visits versus familiar arm 2
Study
mousen: not reported in source
Aged C57BL/6 mice receiving EGF + GHRP6
Comparator
Familiar arm 2
Outcome group
Cognition and memory · Nervous system and cognition
Source sentences
Summary
In the forced alternation Y-maze test, aged-EGF + GHRP6 animals made more visits to the novel arm than to the familiar arm 1 (p = 0.001) or to the familiar arm 2 (p = 0.04).
2 context sentences(design, population, supporting numbers)
Summary · context
The present study evaluated the therapeutic potential of this combination in two preclinical models of cognitive impairment: (i) age-related decline and (ii) impairment induced by intracerebroventricular administration of streptozotocin (STZ).
Summary · context
In both experiments, C57BL/6 mice were used and distributed into three experimental groups, each comprising 14-15 animals per group.
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-4239952403
04AnimalNot a test of GHRP-6 aloneAnimal study (in vivo)Efficacy outcome
In STZ-treated mice, EGF+GHRP6 increased alternation percentage versus STZ-vehicle.
In plain wordsIn mice with STZ-induced cognitive impairment, EGF+GHRP6 increased alternation percentage versus vehicle.
Peptide
GHRP-6
Outcome
IncreaseAlternation percentage in STZ model
Study
mousen: not reported in source
C57BL/6 mice with age-related or STZ-induced cognitive impairment
Comparator
STZ-vehicle group
Outcome group
Cognition and memory · Nervous system and cognition
Source sentences
Summary
STZ-EGF + GHRP6 group exhibited an alternation percentage higher than the STZ-vehicle group (p = 0.03).
2 context sentences(design, population, supporting numbers)
Summary · context
The present study evaluated the therapeutic potential of this combination in two preclinical models of cognitive impairment: (i) age-related decline and (ii) impairment induced by intracerebroventricular administration of streptozotocin (STZ).
Summary · context
In both experiments, C57BL/6 mice were used and distributed into three experimental groups, each comprising 14-15 animals per group.
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-4239952404
05AnimalNot a test of GHRP-6 aloneAnimal study (in vivo)Mechanism
In mice with cognitive impairment, EGF+GHRP6 significantly increased Hmox1 expression.
In plain wordsIn mice with cognitive impairment, EGF+GHRP6 increased Hmox1 gene expression.
Peptide
GHRP-6
Outcome
IncreaseHmox1 expression
Study
mousen: not reported in source
C57BL/6 mice with age-related or STZ-induced cognitive impairment
Outcome group
Receptor activity and mechanism · Nervous system and cognition
Source sentences
Summary
Moreover, EGF + GHRP6 treatment significantly increased the expression of genes associated with antioxidant defense (Hmox1), synaptic plasticity (Creb1), and oligodendrocyte differentiation (Olig1) while concurrently reducing the expression of Nfkb1.
2 context sentences(design, population, supporting numbers)
Summary · context
The present study evaluated the therapeutic potential of this combination in two preclinical models of cognitive impairment: (i) age-related decline and (ii) impairment induced by intracerebroventricular administration of streptozotocin (STZ).
Summary · context
In both experiments, C57BL/6 mice were used and distributed into three experimental groups, each comprising 14-15 animals per group.
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-4239952405
06AnimalNot a test of GHRP-6 aloneAnimal study (in vivo)Mechanism
In mice with cognitive impairment, EGF+GHRP6 significantly increased Creb1 expression.
In plain wordsIn mice with cognitive impairment, EGF+GHRP6 increased Creb1 gene expression.
Peptide
GHRP-6
Outcome
IncreaseCreb1 expression
Study
mousen: not reported in source
C57BL/6 mice with age-related or STZ-induced cognitive impairment
Outcome group
Receptor activity and mechanism · Nervous system and cognition
Source sentences
Summary
Moreover, EGF + GHRP6 treatment significantly increased the expression of genes associated with antioxidant defense (Hmox1), synaptic plasticity (Creb1), and oligodendrocyte differentiation (Olig1) while concurrently reducing the expression of Nfkb1.
2 context sentences(design, population, supporting numbers)
Summary · context
The present study evaluated the therapeutic potential of this combination in two preclinical models of cognitive impairment: (i) age-related decline and (ii) impairment induced by intracerebroventricular administration of streptozotocin (STZ).
Summary · context
In both experiments, C57BL/6 mice were used and distributed into three experimental groups, each comprising 14-15 animals per group.
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-4239952406
07AnimalNot a test of GHRP-6 aloneAnimal study (in vivo)Mechanism
In mice with cognitive impairment, EGF+GHRP6 significantly increased Olig1 expression.
In plain wordsIn mice with cognitive impairment, EGF+GHRP6 increased Olig1 gene expression.
Peptide
GHRP-6
Outcome
IncreaseOlig1 expression
Study
mousen: not reported in source
C57BL/6 mice with age-related or STZ-induced cognitive impairment
Outcome group
Receptor activity and mechanism · Nervous system and cognition
Source sentences
Summary
Moreover, EGF + GHRP6 treatment significantly increased the expression of genes associated with antioxidant defense (Hmox1), synaptic plasticity (Creb1), and oligodendrocyte differentiation (Olig1) while concurrently reducing the expression of Nfkb1.
2 context sentences(design, population, supporting numbers)
Summary · context
The present study evaluated the therapeutic potential of this combination in two preclinical models of cognitive impairment: (i) age-related decline and (ii) impairment induced by intracerebroventricular administration of streptozotocin (STZ).
Summary · context
In both experiments, C57BL/6 mice were used and distributed into three experimental groups, each comprising 14-15 animals per group.
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-4239952407
08AnimalNot a test of GHRP-6 aloneAnimal study (in vivo)Mechanism
In mice with cognitive impairment, EGF+GHRP6 reduced Nfkb1 expression.
In plain wordsIn mice with cognitive impairment, EGF+GHRP6 reduced Nfkb1 gene expression.
Peptide
GHRP-6
Outcome
DecreaseNfkb1 expression
Study
mousen: not reported in source
C57BL/6 mice with age-related or STZ-induced cognitive impairment
Outcome group
Receptor activity and mechanism · Nervous system and cognition
Source sentences
Summary
Moreover, EGF + GHRP6 treatment significantly increased the expression of genes associated with antioxidant defense (Hmox1), synaptic plasticity (Creb1), and oligodendrocyte differentiation (Olig1) while concurrently reducing the expression of Nfkb1.
2 context sentences(design, population, supporting numbers)
Summary · context
The present study evaluated the therapeutic potential of this combination in two preclinical models of cognitive impairment: (i) age-related decline and (ii) impairment induced by intracerebroventricular administration of streptozotocin (STZ).
Summary · context
In both experiments, C57BL/6 mice were used and distributed into three experimental groups, each comprising 14-15 animals per group.
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-4239952408

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
21 Oct 2026, 15:58 UTC
Study results updated
Version 1
9 Oct 2026, 03:13 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.